Resources

05.22.2023

Given the tremendous focus of MA-based companies and investors, we had an opportunity to pen some thoughts which are shared in the attached letter.

05.18.2023

The life sciences venture capital community has long warned against the adverse consequences government price controls for prescription drugs would...

04.26.2023

In the world of Making Medicine, every day should be World IP Day.

04.17.2023

Incubate submitted our feedback to the Centers for Medicare & Medicaid Services regarding its draft guidance for the Medicare Drug Price Negotiation Program.

04.01.2023

03.31.2023

Earlier this week, the National Institutes of Health rejected a petition to initiate “march-in” proceedings.

03.31.2023

Executive Director John Stanford testified before the International Trade Organization.

03.30.2023

See Incubate's blog post from Executive Director John Stanford on his recent testimony before the International Trade Organization about how weakening Intellectual Property protections will damage the early-stage life science ecosystem.

03.09.2023

Today, March 9th, 2023, President Biden released his Fiscal Year (FY) 2024 proposed budget and recommendations. Notably, one proposal indicates that the President seeks to expand price controls established in the Inflation Reduction Act of 2022.

03.06.2023

"But the IRA is changing the calculus in a meaningful — and harmful — way."

02.08.2023

We must bolster the scientific biopharmaceutical ecosystem, not abandon it. 

12.15.2022

Incubate breaks down the Inflation Reduction Act, diving into implications and potential impacts on life science development. Keep up with...